مقايسة البروتين المندمج بالجريان الخلوي BCR-ABL : هل هي طريقة واعدة لاستعراف الابيضاض النقوي المزمن لدى مرضى سوريين ؟

الملخص EN

Philadelphia chromosome exists in 95% of chronic myeloid leukemia (CML) patients, producing BCR-ABL fusion oncoprotein with upregulated tyrosine kinase activity.

Our study aimed to evaluate the BCR-ABL protein flow cytometric assay and estimate its efficacy to identify patients with such aberration.

Twelve Philadelphia-positive (Ph+) patients and twenty Philadelphia-negative (Ph-) healthy individuals were recruited.

Peripheral blood mononuclear cells (PBMCs) were separated using ficoll, Fluorescence intensity values were measured using BCR-ABL protein kit and flow cytometry instrument.

Appropriate statistical tests were used, and a p-value<0.05 was considered statistically significant The MFI mean values of Ph+ patients and Ph- healthy individuals were 525.49 and 16.4, respectively, showing a significant difference between the two groups (p<0.05).

In addition, the presence of Philadelphia chromosome correlated strongly with MFI mean values (p<0.05).

The BCR-ABL fusion protein assay seems efficacious to identify BCR-ABL aberration.